Pharvaris (NASDAQ:PHVS) Shares Down 6% on Insider Selling

Pharvaris N.V. (NASDAQ:PHVS) shares fell 6% on Friday following insider selling activity. The company traded as low as $29.09 and last traded at $29.1550. 163,274 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 190,164 shares. The stock had previously closed at $31.01.

Specifically, insider Peng Lu sold 3,733 shares of the stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $30.06, for a total transaction of $112,213.98. Following the completion of the transaction, the insider owned 62,350 shares in the company, valued at approximately $1,874,241. This represents a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peng Lu sold 15,000 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total value of $453,600.00. Following the transaction, the insider owned 66,083 shares of the company’s stock, valued at $1,998,349.92. The trade was a 18.50% decrease in their position. The SEC filing for this sale provides additional information. In other news, insider Anne Lesage sold 3,700 shares of the stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $30.08, for a total transaction of $111,296.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued at approximately $1,698,016. This represents a 6.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Analysts Set New Price Targets

Several research firms have recently weighed in on PHVS. Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Wall Street Zen downgraded Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Citigroup restated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.73.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six?figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near?term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ?$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ?$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ?$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Pharvaris Stock Performance

The firm has a 50 day simple moving average of $27.62 and a 200 day simple moving average of $26.06. The firm has a market cap of $1.93 billion, a P/E ratio of -8.74 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Sell-side analysts predict that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Pharvaris during the 4th quarter valued at about $35,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pharvaris during the 3rd quarter valued at about $75,000. Barclays PLC bought a new stake in shares of Pharvaris during the 4th quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Pharvaris during the 4th quarter valued at about $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.